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Abstract
Background: Acute Intermittent Porphyria is a genetic disorder of heme metabolism,
characterized by increased levels of porphyrin precursors, δ-aminolevulinic acid (ALA) and
porphobilinogen (PBG). ALA has been reported to generate reactive oxygen species and to cause
oxidative damage to proteins, subcellular structures and DNA. It is known that oxidative stress can
induce apoptosis. The aim of this work was to study the cytotoxic effect of ALA on two
hepatocarcinoma cell lines.
Results: We have determined the impact of ALA on HEP G2 and HEP 3B hepatocarcinoma cell
lines survival as measured by the MTT assay. ALA proved to be cytotoxic in both cell lines however;
HEP G2 was more sensitive to ALA than HEP 3B. Addition of hemin or glucose diminished ALA
cytotoxicity in HEP G2 cells; instead it was enhanced in HEP 3B cells. Because apoptosis is usually
associated with DNA fragmentation, the DNA of ALA treated and untreated cells were analyzed.
The characteristic pattern of DNA fragmentation ladders was observed in ALA treated cells. To
elucidate the mechanisms of ALA induced apoptosis, we examined its effect on p53 expression. No
changes in p53 mRNA levels were observed after exposure of both cell lines to ALA for 24 h.
CDK2 and CDK4 protein levels were reduced after ALA treatment at physiological
concentrations.
Background
Acute Intermittent Porphyria (AIP) is an autosomal dom-
inant inherited disorder because of a partial defect in Por-
phobilinogen Deaminase (PBGD), the third enzyme in
the heme biosynthetic pathway. As a result, the porphy-
rins precursors, δ-aminolevulinic acid (ALA) and Porpho-
bilinogen (PBG) can accumulate [1]. Furthermore, the
free heme pool would decrease and adversely affect P-450
and several important antioxidant enzymes, leading to
impaired hepatic detoxification reactions [2]. Clinically,
the disease is characterized by occasional acute attacks of
abdominal pain and various neuropsychiatric symptoms.
Several therapeutic drugs, anaesthetics and infections are
considered the most frequent precipitating factors of acute
attacks in the Argentinean population [3]. Specific treat-
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hemin [5] and folic acid in combination with glucose [6].
In Northern Sweden, Lithner and Wetterberg [7] and
Hardell et al.[8] have found a clear association between
AIP and hepatocellular carcinoma, also confirmed by oth-
er authors [9].
Moreover, ALA has been demonstrated to produce reac-
tive oxygen species through metal-catalyzed aerobic oxi-
dation and to cause oxidative damage to proteins, lipids
and subcellular structures. Exposure of plasmid pBR322
DNA to ALA produced DNA single-strand breaks [10].
In this study, we have examined the effect of ALA on hu-
man hepatocarcinoma HEP G2 and HEP 3B cell lines via-
bility. Tumor cells were exposed to different ALA
concentrations and ALA-S activity repressed conditions,
produced by hemin or glucose addition to the medium.
DNA fragmentation was also analyzed. Northern blot
analysis for p53 and Western blot analysis for CDK2 and





nyltetrazolium bromide and L-glutamine were obtained
from Sigma Chemical Co. (St. Louis, MO). D-Glucose,
PBS, Dulbeco's Modified Eagles Medium (DMEM) and
antibiotics were obtained from GIBCO BRL.
Cell lines and cell culture
HEP G2 and HEP 3B cell lines (American Type Culture
Collection, Rockville, MD) were derived from a human
hepatocellular carcinoma [11–13]. HEP G2 contained
wild-type p53 [14] and HEP 3B cells contained deleted
p53. Cell lines were grown in total darkness, at 37°C in
5% CO2 atmosphere in Dulbecco's Modified Eagle Medi-
um supplemented with 10% fetal bovine serum, 10,000 U
penicillin, 10,000 µg streptomycin and 2 mM L-
glutamine.
MTT assay
After exposure to drugs, the viability was determined by
the MTT assay following published procedures [15]. Brief-
ly, 40,000–50,000 cells in 500 µl of medium were plated
onto each well of 24-well tissue culture plate. After 24 h of
culture, ALA (0.5–5 mM), Hemin (8–24 µg/ml) or D-glu-
cose (2–3 mg/ml) dissolved in PBS immediately prior to
use, were added to the medium. Cells were cultured for 24
h. After exposure, the medium was aspirated and replaced
with 300 µl of fresh drug-free medium containing 0.5 mg/
ml (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-zo-
lium bromide) MTT. The cells were incubated for an addi-
tional 4 h. This medium containing MTT was removed by
inverting the plate and 200 µl of dimethylsulphoxide
(DMSO) were then added to each well. After 10 minutes
of shaking, absorbance in each well was read in a micro-
plate reader at 570 nm. All experiments included untreat-
ed control cells, they were repeated three times and each
concentration was tested in sextuplicate. Viability was ex-
pressed in terms of population growth, as percent of an
untreated control population with standard error of the
mean (SEM).
Analysis of DNA fragmentation
Treated cells were grown in 75 cm3 flasks. Both attached
and unattached cells were harvested, washed with PBS, re-
suspended in TNE solution (10 mM Tris-HCI, pH 7.6; 140
mM sodium chloride; 1 mM EDTA), and lysed at 37°C in
2 ml of extraction buffer (10 mM Tris-HCI, pH8.0; 100
mM EDTA, pH 8.0; 20 µg/ml pancreatic RNase; 0.5%
SDS). After 2 h, proteinase K was added at a final concen-
tration of 100 µg/ml and the mixture was incubated for
another 3 h at 50°C. The DNA was extracted twice with
equal volumes of phenol and once with chloroform. The
DNA was then precipitated with 0.1 vol of sodium acetate
(pH 4.8) and 2.5 vol of ethanol at -20°C overnight and
pelleted at 13,000 g for 30 min. Samples were electro-
phoresed in 2% (w/v) agarose gel and DNA was visualized
by ethidium bromide staining.
Northern blot analysis
Total RNA (40 µg), from exponentially growing cells treat-
ed with different concentrations of ALA (0.5–5 mM) dur-
ing 24 h, was prepared by Chomsinsky and Sacchi [16]
method, size-fractionated on 1% agarose/5% formalde-
hyde gels, transferred onto nylon membrane Hybond-N+
(Amersham Pharmacia Biotech), and ultraviolet cross-
linked. The blots were then prehybridized and hybridized
with pTRI-p53-Human or pTRI-GAPDH-Mouse (Ambi-
on) to 65°C with Ultrahyb solution (Ambion) and
washed as manufacturer described. Blots were exposed to
AGFA films at -70°C and developed. cDNA probes were
labeled with [α-32P]ATP (3,000 Ci/mmol) using Kleanow
(Biolabs) and random primers, for 2 hours at 37°C. Inten-
sity of bands were analysed with ImageMaster (Amersham
Pharmacia Biotech).
Western blot analysis
Exponentially growing cells (5 × 106/25 ml) were treated
with different concentrations of ALA (0.5–5 mM). After
24 h of incubation, cells were washed with PBS and lysed
in 500 µl of RIPA buffer (50 mM Tris pH 7.4; 150 mM Na-
CI; 20 mM EDTA pH 8; 0.1% SDS). After sonication (3 ×
15 s) and 30 min incubation with PMSF (10 mg/ml) at
4°C, cell lysates were centrifuged at 10,000 g for 10 min at
4°C. Protein content of supernatants was determined by
Bradford protein assay. Cell lysates containing equalPage 2 of 6
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polyacrylamide gel electrophoresis (PAGE). Proteins were
transferred onto nitrocellulose membranes Hybond ECL
(Amersham Pharmacia Biotech) at 300 mA for 1 hour at
4°C using Towbin buffer (25 mM Tris; 192 mM glycine;
3.5 mM SDS; 10% Methanol; pH 8.3). Membranes were
blocked by incubation in TBS (20 mM Tris; 137 mM NaCl;
0.05 % Tween 20; pH 7.6) containing 5% dry low fat milk
for 1 hour at room temperature. Blots were probed with
either anti-CDK2 (1:300), anti-CDK4 (1:300) or anti-ac-
tin (1:100) goat polyclonal antibody (Santa Cruz Biotech,
Santa Cruz, CA). Immune complexes were detected using
donkey anti goat secondary antibody (1:1,500) (Santa
Cruz Biotech, Santa Cruz, CA) and were visualized using
ECL reagents (Amersham Pharmacia). Intensity of bands
was analyzed with Image Master (Amersham Pharmacia
Biotech).
Results
Cytotoxic effects of ALA in Human Cancer Cells
Human hepatocarcinoma cells were treated with various
concentrations (0.5–5 mM) of ALA and the viability of
cells was determined (Figure 1). ALA was toxic to both
hepatocarcinoma cell lines. In HEP G2 cells, cytotoxicity
occurred after exposure to 0.5 mM ALA for 24 h (growth
inhibition: 30%) and the highest growth inhibition
(70%) was observed with the highest ALA concentration
(5 mM). HEP 3B cells were more resistant to ALA than
HEP G2 cells, exhibiting only 12% growth inhibition after
exposure to 0.5 mM ALA for 24 h and a 40% growth inhi-
bition with 5 mM ALA. The strange shape of the viability
curves obtained in both cases, with a restoration of con-
trol viability with 2 mM ALA, cannot be explained.
Hemin and D-Glucose effect
Simultaneous treatment of the HEP G2 cells with ALA (0.5
mM) and non-toxic concentrations of hemin (8–24 µg/
ml) for 24 h resulted in a significant decrease in sensitivity
to ALA (Figure 2), reverting its cytotoxic effect. It is worth
noting that treatment of HEP G2 cells with hemin alone
stimulated cell survival (20% over control). However, the
same treatment of HEP 3B (ALA and hemin) increased
ALA toxicity.
Alike hemin, simultaneous treatment of the HEP G2 cells
with ALA (0.5 mM) and D-glucose (2–3 mg/ml) for 24 h
resulted in about two-fold decrease in sensitivity to ALA
(Figure 3). And again the same treatment of HEP 3B (ALA
and D-glucose) enhanced ALA cytotoxicity.
Figure 1
Cytotoxic effects of ALA. Human hepatocarcinoma cell
lines (HEP G2 (circles) HEP 3B (squares)) were grown in the
absence or in the presence of increasing ALA concentrations
(0.5 to 5 mM) and the viability of cells was determined by the
MTT assay. Viability was expressed in terms of population
growth, as percent of an untreated control population with
standard error of the mean (SEM).
ALA (mM)























Hemin effect on ALA toxicity. The effect of Hemin was
determined by exposing HEP G2 and HEP 3B cells to 0.5 mM
ALA without (white) or with 16 µg/ml Hemin (grey) for 24 h
before the MTT assay was performed. Controls were grown
with 16 µg/ml Hemin alone (black). Viability was expressed in
terms of population growth, as percent of an untreated con-
trol population with standard error of the mean (SEM).
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As shown in Figure 4a, after 24 h exposure of HEP G2 cells
to ALA (1–5 mM) both attached and unattached cells were
harvested. In each case, nucleosomal DNA ladders, typical
of apoptosis, were visible on agarose gel after staining
with ethidium bromide. When HEP 3B cells were treated
under the same conditions, nucleosomal DNA ladders
were much less visualized (Figure 4b). Apoptosis was also
corroborated morphologically by phase contrast micros-
copy in both cell lines. The decrease in viability was due
to cytotoxicity as observed under phase contrast microsco-
py. ALA caused hepatoma cells first to shrink and then
gradually to become dettached, starting about 14 hours
after treatment as observed by phase contrast microscopy
(data not shown).
Modulation of p53 and cell cycle in HEP G2 cells
To elucidate the mechanisms of ALA causing apoptosis se-
lectively, we have examined the effect of ALA on p53
mRNA levels. No any change in mRNA p53 levels for 24 h
was observed in HEP G2 cells (Figure 5). Only at concen-
trations as high as 5 mM ALA, p53 mRNA expression was
25% diminished.
When CDK2 and CDK4 protein levels were analyzed in
HEP G2 cells after exposure to ALA for 24 h (Figure 6),
both kinases decreased with increased ALA concentra-
tions, up to 2 mM. At concentrations above 2 mM protein
content increased reaching basal levels at 5 mM (Figure
6).
Discussion
The heme precursor ALA accumulates under pathological
conditions, such as AIP, tyrosinosis and lead poisoning,
diseases often linked with increased liver cancer incidence
[17]. The reactive oxygen species generated upon ALA
metal-catalyzed oxidation, promote the formation of sev-
eral radical-induced base degradation products in isolated
and cellular DNA [17]. ALA is the precursor of Protopor-
phyrin IX (Proto IX). Exogenous ALA bypasses the feed-
back control and may induce Proto IX accumulation.
Since heme-containing enzymes are essential for energy
metabolism, every nucleated cell should have at least a
minimal capacity to synthesize Proto IX and this is the ra-
tional for the use of Photodynamic Therapy [18].
ALA proved to be cytotoxic in neuroblastoma cells. This
cytotoxic effect of ALA could be diminished by heme, pre-
sumably through modulation of ALA synthesis [19].
Here we have demonstrated the cytotoxic effect of ALA on
two human hepatocellular carcinoma cell lines HEP G2
and HEP 3B, which was greater on the former. ALA effect
would be attributed to its accumulation in HEP G2 cells,
as it was shown by its reduction after simultaneous expo-
Figure 3
Glucose effect on ALA toxicity. The effect of Glucose
was determined by exposing HEP G2 and HEP 3B cells to 0.5
mM ALA without (white) or with 2 mg/ml glucose (grey) for
24 h before the MTT assay was performed. Controls were
grown with 2 mg/ml glucose alone (black). Viability was
expressed in terms of population growth, as percent of an
untreated control population with standard error of the
mean (SEM).















DNA fragmentation analysis in human hepatocarci-
noma cells undergoing ALA-induced apoptosis. HEP
G2 (a) or HEP 3B (b) cells were treated with ALA (0; 1; 2 or
5 mM) and DNA fragmentation was examined 24 h later.
HEP 3B cells were also treated with Etoposide (Eto, 5 µM),
used as positive control.Page 4 of 6
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ALA-S activity. There is evidence that following the expo-
sure to external ALA, there is induction of endogenous
ALA synthesis, and that ALA uptake is higher in more rap-
idly proliferating cells [20]. The strange shape of the via-
bility curves is difficult to explain within the context of
these experiments and could probably be due to different
ALA and/or PPIX accumulation, which will be measured
in future assays.
In HEP G2 cells, protection by hemin would be due to in-
duction of the HO-1 gene, and increased formation of bi-
lirubine, through heme degradation with its known free
radicals scavenger effect [21,22]. Glucose protection could
be attributed to overcoming reduced glucose uptake pro-
voked by ALA. ALA was reported to affect cultured chick
embryo neuronal and glial cells by decreasing glucose up-
take [23].
In HEP 3B cells, treatment with ALA and hemin or glucose
produced increased cytotoxicity, indicating that the mech-
anism of ALA action involved would certainly be differ-
ent.
Apoptosis is a physiological event occurring in response
to multiple stimuli including growth factor withdrawal,
radiation therapy and presence of chemotherapeutic
agents. Several mechanisms regulate the apoptotic proc-
ess, such as induction of a p53-dependent-pathway after
DNA-damaging agents, modulation by the bcl2 family of
proteins, and activation of some effectors including the
interleukin-converting enzyme (ICE) family of proteases
and endonucleases [24,25].
Interestingly, ALA produced apoptosis visualized by DNA
ladders, but its action did not appear to correlate with the
p53 status; while HEP 3B p53 null cells are relatively re-
sistant to ALA-induced apoptosis, HEP G2 p53 wild type
cells are very sensitive to ALA-induced apoptosis. Howev-
er, the treatment did not alter mRNA p53 levels as re-
vealed by Northern blot analysis suggesting that apoptosis
would be occurring through other mechanism, p53 inde-
pendent.
CDKs have been implicated as modulators of apoptosis
[26]. Some important influences that may have an impact
on susceptibility to apoptosis include altered generation
of reactive oxygen or nitric oxide intermediates or propen-
sity for mitochondrial damage or protease activation.
The mammalian cell cycle is controlled by sequential acti-
vation and inactivation of the CDKs family, which are ac-
tivated by cyclins and inhibited by CKIs. The regulators
that operate in the different phases of the cell cycle are var-
ious.
In our experiments, CDK2 and CDK4 protein levels de-
creased with ALA treatment preventing cells proliferation.
Considering that both kinases are involved in cell cycle
progression, diminution of their levels would induce G1
arrest and lead to the onset of the apoptotic process. When
ALA was added to the medium at supraphysiological con-
centrations (higher than 3 mM), the rate of death cells
were so high that the measured kinases levels would only
correspond to a minimal proportion of viable cells. Per-
haps, these cells represent a part of the population in S
phase and therefore, with high levels of the kinases neces-
sary to duplicate. These results prompted us to speculate
that ALA toxic effect would be effective only in those cells
which would be able to enter in arrest and would not exert
any effect on those which are cycling. Further studies are
in progress to further support our hypothesis. Disruption
of the regulatory system controlling G1 phase progression
is a common event in human hepatocarcinogenesis. Over-
coming alterations that have occurred in the G1 phase reg-
Figure 5
p53 mRNA expression in HEP G2 cells under ALA
treatment. Total RNA was isolated after treatment of cells
with ALA (0–5 mM) during 24 h and hybridized with cDNA
p53 specific probe and normalized relative to GAPDH. Inten-
sity of bands were analysed with ImageMaster.
Figure 6
Western blot analysis of CDK4 and CDK2. Proteins
were isolated after treatment of cells with ALA (0–5 mM)
during 24 h. Proteins were normalized to 50 µg per lane and
the amount of CDK2 and CDK4 was detected using polyclo-
nal antibodies and visualized using ECL reagents. Intensity of
bands was analysed with ImageMaster.Page 5 of 6
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hepatocellular carcinoma [[27] and references there in].
In summary, ALA has a markedly cytotoxic effect on hepa-
tocarcinoma cell lines at physiological levels, which could
be attributed to an enhancement of apoptosis, independ-
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